HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

AbstractOBJECTIVE:
There is limited information from large-scale prospective studies regarding the prediction of type 1 diabetes by specific types of pancreatic islet autoantibodies, either alone or in combination. Thus, we studied the extent to which specific autoantibodies are predictive of type 1 diabetes.
RESEARCH DESIGN AND METHODS:
Two cohorts were derived from the first screening for islet cell autoantibodies (ICAs) in the Diabetes Prevention Trial-Type 1 (DPT-1). Autoantibodies to GAD 65 (GAD65), insulinoma-associated antigen-2 (ICA512), and insulin (micro-IAA [mIAA]) were also measured. Participants were followed for the occurrence of type 1 diabetes. One cohort (Questionnaire) included those who did not enter the DPT-1 trials, but responded to questionnaires (n = 28,507, 2.4% ICA(+)). The other cohort (Trials) included DPT-1 participants (n = 528, 83.3% ICA(+)).
RESULTS:
In both cohorts autoantibody number was highly predictive of type 1 diabetes (P < 0.001). The Questionnaire cohort was used to assess prediction according to the type of autoantibody. As single autoantibodies, ICA (3.9%), GAD65 (4.4%), and ICA512 (4.6%) were similarly predictive of type 1 diabetes in proportional hazards models (P < 0.001 for all). However, no subjects with mIAA as single autoantibodies developed type 1 diabetes. As second autoantibodies, all except mIAA added significantly (P < 0.001) to the prediction of type 1 diabetes. Within the positive range, GAD65 and ICA autoantibody titers were predictive of type 1 diabetes.
CONCLUSIONS:
The data indicate that the number of autoantibodies is predictive of type 1 diabetes. However, mIAA is less predictive of type 1 diabetes than other autoantibodies. Autoantibody number, type of autoantibody, and autoantibody titer must be carefully considered in planning prevention trials for type 1 diabetes.
AuthorsTihamer Orban, Jay M Sosenko, David Cuthbertson, Jeffrey P Krischer, Jay S Skyler, Richard Jackson, Liping Yu, Jerry P Palmer, Desmond Schatz, George Eisenbarth, Diabetes Prevention Trial-Type 1 Study Group
JournalDiabetes care (Diabetes Care) Vol. 32 Issue 12 Pg. 2269-74 (Dec 2009) ISSN: 1935-5548 [Electronic] United States
PMID19741189 (Publication Type: Journal Article)
Chemical References
  • Autoantibodies
  • Receptor-Like Protein Tyrosine Phosphatases, Class 8
  • Glutamate Decarboxylase
  • glutamate decarboxylase 2
Topics
  • Autoantibodies (analysis)
  • Cohort Studies
  • Diabetes Mellitus, Type 1 (diagnosis, enzymology, immunology, prevention & control)
  • Glutamate Decarboxylase (immunology)
  • Humans
  • Islets of Langerhans (immunology)
  • Predictive Value of Tests
  • Prospective Studies
  • Receptor-Like Protein Tyrosine Phosphatases, Class 8 (immunology)
  • Surveys and Questionnaires

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: